The consistent OS data across geographies and the positive head-to-head HARMONi-2 data against Keytruda significantly de-risk the ivonescimab program ahead of the November PDUFA. Traders should watch for potential pre-approval investor events and any FDA advisory committee briefing documents. The stock is likely to re-rate higher as the probability of approval and peak sales estimates increase.
Price Chart
Executive Summary
Summit Therapeutics presented updated overall survival (OS) data from the global Phase III HARMONi trial (ivonescimab + chemo in EGFR-mutated NSCLC) and detailed OS results from the China-based HARMONi-2 trial (ivonescimab monotherapy vs. pembrolizumab) at WCLC 2026. The HARMONi data showed a consistent OS benefit with a hazard ratio of 0.76 (nominal p=0.0151) in the global ITT population, with western patients now showing a similar HR of 0.76, reinforcing the drug's profile ahead of the November 14, 2026 PDUFA date. HARMONi-2 showed a statistically significant OS benefit for ivonescimab over pembrolizumab (HR 0.73, p=0.009), further strengthening the clinical case for the asset across multiple lung cancer settings.
Key Facts
- Updated HARMONi OS HR of 0.76 (95% CI: 0.61-0.95; nominal p=0.0151) in global ITT population at June 2026 data cut-off.
- Western patient subgroup OS HR improved to 0.76 (95% CI: 0.52-1.10) with longer follow-up (median 23.2 months), matching the global trend.
- HARMONi-2 showed ivonescimab monotherapy beat pembrolizumab on OS with HR 0.73 (95% CI: 0.57-0.95; p=0.009), including a 7.6-month median OS advantage (30.8 vs 22.6 months).
- PDUFA goal date for the ivonescimab BLA in the U.S. is November 14, 2026.
- No new safety signals were observed in either HARMONi or HARMONi-2 with longer follow-up.
Financial Impact
Positive catalyst for SMMT stock; ivonescimab is the sole pipeline asset. Approval in EGFR-mutated NSCLC (HARMONi) represents a multi-billion-dollar peak sales opportunity. HARMONi-2 data supports potential label expansion into first-line PD-L1 positive NSCLC, significantly increasing the addressable market.
Risk Factors
- The HARMONi OS benefit did not reach statistical significance at the primary analysis (p=0.057), and the updated analysis uses a nominal p-value, which may be a point of FDA scrutiny.
- HARMONi-2 is a single-region China study; the FDA may require a global confirmatory trial for a first-line indication.
- Competition from other bispecific antibodies and antibody-drug conjugates in the NSCLC space is intense.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001599298-26-000081 |
| Document: a2026_prx0915xharmoniltf.htm | 0001599298-26-000081 |
| Document: 0001599298-26-000081-index-headers.html | 0001599298-26-000081 |
| Document: 0001599298-26-000081-index.html | 0001599298-26-000081 |
| Document: 0001599298-26-000081.txt | 0001599298-26-000081 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $17.40 $17.85 | ▲ +2.59% | ▲ +1.77% | $16.75 (−3.71%) |
Sep 14, 2026 18d ago | 8-K | $18.42 $16.90 | ▼ −8.25% | ▼ −8.36% | $16.75 (−9.04%) |
Sep 3, 2026 29d ago | 8-K | $17.13 $17.55 | ▲ +2.45% | ▲ +3.60% | $16.75 (−2.19%) |
Aug 26, 2026 5w ago | 8-K | $14.23 $14.60 | ▲ +2.60% | ▲ +2.72% | $16.75 (+17.74%) |
Aug 5, 2026 8w ago | 8-K | $13.53 $15.10 | ▲ +11.60% | ▲ +11.25% | $16.75 (+23.84%) |
Jul 22, 2026 10w ago | 8-K | $14.74 $12.80 | ▼ −13.16% | ▼ −10.76% | $16.75 (+13.67%) |
Jun 12, 2026 16w ago | Insider Cluster | $14.01 $13.75 | ▼ −1.86% | ▼ −2.53% | $16.75 (+19.59%) |
Jun 12, 2026 16w ago | Institutional Cluster | $14.01 $13.75 | ▼ −1.86% | ▼ −2.53% | $16.75 (+19.59%) |
Jun 11, 2026 16w ago | Institutional Cluster | $13.08 $14.07 | ▲ +7.57% | ▲ +7.14% | $16.75 (+28.10%) |
Jun 9, 2026 16w ago | S-3ASR | $13.05 $13.88 | ▼ −6.36% | ▼ −2.93% | $16.75 (−28.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access